We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02288975
Recruitment Status : Recruiting
First Posted : November 13, 2014
Last Update Posted : March 9, 2017
Information provided by (Responsible Party):
Domonkos Trásy, Szeged University

Brief Summary:
The aim of the study is to investigate the effect of CytoSorb® treatment within the first 48 hours of septic shock on organ dysfunction, microcirculation and on the cytokine storm as monitored by leukocyte activation and inflammatory mediators.

Condition or disease Intervention/treatment
Sepsis Septic Shock Device: CytoSorb 300ml device (3804606CE01)

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: The Effect of Early Cytokine Absorption on the Systemic Inflammatory Response Syndrome and Organ Dysfunction in the First 48 Hours of Septic Shock
Study Start Date : October 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock
U.S. FDA Resources

Group/Cohort Intervention/treatment
Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
Device: CytoSorb 300ml device (3804606CE01)
Patients with septic shock will get routine ICU care.

Primary Outcome Measures :
  1. Cytokine response [ Time Frame: First 48 hours of septic shock ]
    Cytokine response: procalcitonin, C-reactive protein, interleukin-1, interleukin-1ra, interleukin-6, interleukin-8, interleukin-10, Tumor Necrosis Factor- α

  2. Organ dysfunctions [ Time Frame: First 48 hours of septic shock ]
    Organ dysfunctions: SOFA-scores, neurologic function (Glasgow coma scale), hemodynamic function (PiCCO parameters, ScvO2, lactate, dCO2), pulmonary function (gas exchange, pulmonary mechanics, Acute Respiratory Distress Syndrome classification (BERLIN)), renal function (KDIGO-, RIFLE-scores), gastrointestinal function (liver, GIT function, hematology (hemostasis, qualitative blood count)

Secondary Outcome Measures :
  1. Leukocyte function [ Time Frame: First 48 hours of septic shock ]
    Leukocyte function: heterogeneity of leukocyte cell population in the bloodstream, T-cell activation and apoptosis, leukocyte inflammatory markers expression

  2. Microcirculation [ Time Frame: First 48 hours of septic shock ]
    Microcirculation: orthogonal polarization spectroscopy (OPS), gastric tonometry

Other Outcome Measures:
  1. Length of intensive care unit stay, [ Time Frame: First 48 hours of septic shock ]
  2. Length of hospital stay [ Time Frame: First 48 hours of septic shock ]
  3. Mortality [ Time Frame: First 48 hours of septic shock ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
ICU patients with septic shock of medical origin

Inclusion Criteria:

  • Signs of hypoperfusion: serum lactate >2 mmol/L, low central venous oxygen saturation (ScvO2) (<70%) or high ScvO2 (>85%), metabolic acidosis, oligo-anuria, high venous-to-arterial CO2-gap (dCO2 >6 mm Hg)
  • Hemodynamic support with vasopressors
  • Procalcitonin level ≥ 3 ng/ml
  • Invasive hemodynamic monitoring
  • Written informed content

Exclusion Criteria:

  • Patients under 18 years
  • Pregnancy (bHCG test positivity)
  • Surgical intervention in context with the septic insult
  • New York Heart Association IV heart failure
  • Acute coronary syndrome
  • Need for acute or chronic hemodialysis
  • Acute haematological malignancies
  • Cardiogenic shock
  • Post cardiopulmonary resuscitation care
  • Immunosuppression, systemic steroid therapy (>10mg prednisolon/day)
  • Human immunodeficiency virus infection (HIV) and active AIDS
  • Patients with donated organs
  • Thrombocytopenia (<20.000/ml)
  • More than 10%-of body surface area with third degree burn

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02288975

Contact: Domonkos Trásy, MD +36 62 - 545 168 trasydom@gmail.com

Department of Anaesthesiology and Intensive Therapy Recruiting
Szeged, Csongrád, Hungary, H-6725
Contact: Domonkos Trásy, MD    +36 62 - 545 168    trasydom@gmail.com   
Sponsors and Collaborators
Domonkos Trásy

Responsible Party: Domonkos Trásy, Ph.D. student; Department of Anaesthesiology and Intensive Therapy, Szeged University
ClinicalTrials.gov Identifier: NCT02288975     History of Changes
Other Study ID Numbers: CytoSorb-2014
First Posted: November 13, 2014    Key Record Dates
Last Update Posted: March 9, 2017
Last Verified: March 2017

Keywords provided by Domonkos Trásy, Szeged University:
extracorporeal blood purification
septic shock

Additional relevant MeSH terms:
Shock, Septic
Systemic Inflammatory Response Syndrome
Pathologic Processes